Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
TREMELIMUMAB-ACTL 25 MG/1.25ML IV SOLN (NDC 00310450525) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 3, 2026 , from http://ppman.hank.ai/transparency/procedure/00310450525/by-state?code_type=NDC
“TREMELIMUMAB-ACTL 25 MG/1.25ML IV SOLN (NDC 00310450525) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/00310450525/by-state?code_type=NDC. Accessed
November 3, 2026 .
“TREMELIMUMAB-ACTL 25 MG/1.25ML IV SOLN (NDC 00310450525) by State,” HANK Price Transparency ,
accessed November 3, 2026 ,
http://ppman.hank.ai/transparency/procedure/00310450525/by-state?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
NDC · across United States
00310450525 — Tremelimumab-actl 25 Mg/1.25ml IV Soln
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$6,743
National median
$5,037 – $7,396
IQR (p25 – p75)
9
hospitals filing
3
states
Walking in without insurance?
Cash / self-pay price
Cash median
$5,470
vs. negotiated
-18.9%
Hospitals reporting
11
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 00310450525 (NDC), with interquartile range
State Median p25 p75
CA $6,962 $5,819 $7,459
MI $5,362 $4,308 $6,697
HI $5,037 $2,487 $6,782